Risk Evaluation and Mitigation Strategy (REMS)

I. GOALS
The goals of the Adempas Risk Evaluation and Mitigation Strategy (REMS) are:

1. To inform prescribers, patients, and pharmacists about the serious risk of teratogenicity and safe-use conditions for Adempas

2. To minimize the risk of fetal exposure and adverse fetal outcomes in Females of Reproductive Potential (FRP) prescribed Adempas
   a. Females who are pregnant must not be prescribed Adempas
   b. Females taking Adempas must not become pregnant

II. REMS ELEMENTS

A. Medication Guide
A Medication Guide will be dispensed with each Adempas prescription in accordance with 21 CFR 208.24.

The Adempas Medication Guide is part of the REMS and is appended.

B. Elements to Assure Safe Use

1. Healthcare providers (HCPs) who prescribe Adempas will be specially certified.
   a. Bayer will ensure that HCPs who prescribe Adempas are specially certified. HCPs will agree on the Adempas REMS Prescriber Enrollment and Agreement Form to:
i. Read the full prescribing information (PI), the Adempas Medication Guide, and the Prescriber Guide for the Adempas REMS Program

ii. Enroll all females in the Adempas REMS Program by completing the designated sections of the Adempas Patient Enrollment and Consent Form

iii. Determine whether each female is of reproductive potential as defined in the Prescriber Guide for the Adempas REMS Program

iv. Advise all females that Adempas is only available through a restricted distribution program called the Adempas REMS Program

v. For FRP (as defined by Prescriber Guide for the Adempas REMS Program):
   1. Review the Adempas Medication Guide and the Adempas REMS Program Guide for Females Who Can Get Pregnant with the patient prior to initiating treatment
   2. Educate FRPs about the risk of teratogenicity, the need to use reliable contraception as defined in the Prescriber Guide for the Adempas REMS Program during Adempas treatment and for one month following treatment discontinuation, and her medical options in the event of unprotected sexual intercourse or known or suspected contraception failure.
   3. Order and review a pregnancy test prior to initiation of Adempas treatment, monthly during treatment, and for one month following treatment discontinuation
   4. Counsel the FRP if she is not complying with the required testing or if she is not using appropriate contraception as specified for FRP
   5. Counsel FRP to immediately contact her healthcare provider if she misses a menstrual period or suspects that she is pregnant
   6. Report any changes in reproductive status by completing the Reproductive Potential Status Form within ten (10) business days of becoming aware of the change

vi. For Pre-Pubertal Females of Non-Reproductive Potential (FNRP) (as defined by the Prescriber Guide for the Adempas REMS Program):
   1. Educate the pre-pubertal female and/or a parent/guardian about the risk of teratogenicity
   2. Review the Adempas Medication Guide with the patient and/or a parent/guardian
3. Counsel the pre-pubertal female and/or parent/guardian to immediately contact her healthcare provider if she begins to menstruate

4. Evaluate pre-pubertal females age 8 or older at least annually for any change in reproductive status and complete the Reproductive Potential Status Form

5. Report any change in reproductive status by completing the Reproductive Potential Status Form within 10 business days of becoming aware of the change

vii. For Post-Menopausal FNRP (as defined by the Prescriber Guide for the Adempas REMS Program):

1. Report any misclassification in reproductive status by completing the Reproductive Potential Status Form within 10 business days of becoming aware of the change

viii. Report any pregnancy during Adempas treatment to Bayer with all available information.

b. Bayer will:

i. Ensure that prescribers’ enrollment information and date of agreement are linked to their enrolled patients’ information in a validated secure database

ii. For all females, ensure that the patient information from a new prescriber is linked in the Adempas REMS Program database with certification information from the prior prescriber

iii. Ensure that the Adempas REMS Program Coordinating Center annually contacts the prescriber of a Pre-Pubertal Female to ensure that the prescriber verified the Pre-Pubertal Female’s reproductive status by completing and submitting the Reproductive Potential Status Form

iv. Maintain a validated secure database of certified prescribers in the Adempas REMS Program. Bayer will ensure that prescribers’ certification requirements are met and may de-enroll noncompliant prescribers until the requirements are met

v. Ensure all materials listed in or appended to the Adempas REMS will be available through the Adempas REMS Program Website (www.adempasREMS.com) or by calling the Adempas REMS Program Coordinating Center at 1-855-423-3672.

c. The following materials are part of the Adempas REMS Program and are appended:
2. Pharmacies, practitioners, and healthcare settings (dispensers) that dispense Adempas will be specially certified.

Outpatient Dispensing

a. Bayer will ensure that pharmacies, practitioners, and healthcare settings that dispense Adempas are specially certified. Bayer will ensure that to be certified, pharmacies, practitioners, and healthcare settings that dispense Adempas attest that they will:

i. Verify that the patient’s prescriber is enrolled in the Adempas REMS Program

ii. Verify that females are enrolled in the Adempas REMS Program prior to dispensing each prescription of Adempas

iii. Train all dispensing staff on the Adempas REMS Program procedures and REMS materials prior to dispensing Adempas

iv. Dispense Adempas only to patients who have a prescription written by an enrolled prescriber in the Adempas REMS Program

v. Dispense Adempas only to females who are enrolled in the Adempas REMS Program and have a prescription written by an enrolled prescriber in the Adempas REMS Program

vi. Receive and accept a Patient Enrollment and Consent Form only from the Adempas REMS Program Coordinating Center

vii. Verify reproductive status of all females with information provided by the REMS Coordinating Center prior to dispensing each prescription of Adempas

viii. Not transfer Adempas to any pharmacy, practitioner, or health-care setting not certified by the Adempas REMS program
For FRP (as defined in the *Prescriber Guide for the Adempas REMS Program*):

1. Counsel FRP on the risk of serious birth defects and the need to use reliable contraception (as defined in the *Prescriber Guide to the Adempas REMS Program for Females*) during Adempas treatment and for one month after stopping Adempas treatment.

2. Inform FRP of the requirement to complete a pregnancy test every month and to inform her prescriber immediately if she misses a menstrual period or suspects that she may be pregnant.

3. Dispense up to a 30-day supply of Adempas to FRP only upon completing the following process:
   a) Obtain confirmation from FRP that the pregnancy testing was completed.
   b) If unable to obtain confirmation from FRP that the pregnancy testing was completed, or if the FRP cannot be reached, obtain confirmation from the patient’s prescriber.
   c) If the prescriber for the FRP cannot confirm that the pregnancy testing was completed, the pharmacy must remind the prescriber of his or her obligation to order and review monthly pregnancy tests.
   d) Ask the prescriber whether he or she authorizes the refill of Adempas. The FRP is eligible to receive a 30-day supply of Adempas only if the prescriber authorizes the refill.

   vi. Notify Bayer of any reports of pregnancy.
   vii. Provide dispensing data for all enrolled patients to the Adempas REMS Program.
   viii. Agree that they may be audited by the FDA, Bayer, or a third party designated by Bayer.

b. Bayer will:

   i. Ensure the Adempas REMS Program Coordinating Center notifies certified pharmacies of a patient’s change in reproductive status within one business day of receipt of a completed *Reproductive Potential Status Form*.

*Inpatient Dispensing*
a. Only inpatient pharmacies (including, but not limited to, hospitals, long-term care facilities, prisons, and state psychiatric units) that are certified in the Adempas REMS Program may stock Adempas for patients being treated in the inpatient setting

i. In order to become certified in the Adempas REMS Program, an authorized representative must complete and submit an Adempas REMS Program Inpatient Pharmacy Enrollment Form, agreeing to:

1. Establish systems, protocols, or other measures to ensure the REMS requirements are met

2. Dispense only after contacting the Adempas REMS Program Coordinating Center to confirm the inpatient is under the care of a HCP certified in the Adempas REMS program

3. Not transfer Adempas to any pharmacy, practitioner, or healthcare setting not certified by the Adempas REMS program

4. Notify Bayer of reports of pregnancies

5. Develop a process to track compliance with the conditions above and provide information about its compliance to Bayer upon request

6. Dispense no more than a 15-day temporary supply of Adempas to any patient upon discharge from the healthcare facility

ii. Bayer will ensure that if an inpatient pharmacy needs Adempas and is not enrolled in the Adempas REMS Program, the inpatient pharmacy can contact the Adempas REMS Program Coordinating Center for assistance in obtaining up to a 15-day supply of Adempas for a specific inpatient while initiating enrollment.

b. The following materials are part of the REMS and are appended:

- Adempas REMS Program Inpatient Pharmacy Enrollment Form

3. Adempas will be dispensed to patients with evidence or other documentation of safe-use conditions

a. Bayer will ensure that to become enrolled, or when changing prescribers, each female must complete the designated sections of the Adempas Patient Enrollment and Consent Form.
i. By completing the *Adempas Patient Enrollment and Consent Form* each FRP acknowledges that she has:

1. Been counseled on the risks of Adempas, including the risk of serious birth defects
2. Read the *Adempas Medication Guide* and the *Adempas REMS Program Guide for Females Who Can Get Pregnant*
3. Been counseled that Adempas is only available through a restricted distribution program under a REMS
4. Agreed to be contacted prior to each dispensing of Adempas to obtain confirmation that pregnancy testing was completed
5. Agreed to be counseled each month by the pharmacy on the need to use reliable contraception during Adempas treatment and for one month after stopping Adempas treatment
6. Agreed to have a pregnancy test every month during Adempas treatment and for one month after stopping Adempas
7. Agreed to immediately notify her healthcare provider if she misses a menstrual period or suspects that she is pregnant
8. Agreed to be contacted by Bayer if she becomes pregnant while on Adempas or within one month after stopping Adempas

**C. Implementation System**

The Implementation System will include the following:

a. Bayer will maintain a validated secure database of enrolled prescribers, certified pharmacies, enrolled females, and Adempas dispensing data from certified pharmacies to monitor and evaluate implementation of the elements provided for under Sections B.2. and B.3 above.

b. Bayer will monitor the distribution of Adempas to ensure that the drug is only shipped to certified pharmacies.

c. Bayer will track Adempas dispensing data and monitor certified dispensers to ensure compliance with the Adempas REMS Program and institute corrective actions if they are non-compliant.

d. Bayer will monitor and evaluate the implementation of the elements provided for under Sections B.2. and B.3 above and take steps to work to improve implementation of these elements if needed.
e. Bayer will maintain an Adempas REMS Program Coordinating Center to support patients, prescribers, certified pharmacies, and distributors in interfacing with the Adempas REMS Program.

f. Bayer will audit all outpatient certified pharmacies, distributors and the Adempas REMS Coordinating Center within 180 days after REMS approval to ensure the Adempas REMS Program is implemented as directed. Thereafter, Bayer will include the certified pharmacies, distributors and the Adempas REMS Coordinating Center in the company’s annual audit plan. Corrective actions will be instituted if noncompliance is found.

g. Bayer will ensure that all materials listed in or appended to the Adempas REMS Program will be available through the Adempas REMS Program Website (www.adempasREMS.com) or by calling the Adempas REMS Program Coordinating Center at 1-855-423-3672.

D. Timetable for Submission of Assessments

Bayer will submit REMS Assessments to FDA 6 months and 12 months from the date of initial approval of the REMS, and annually thereafter. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. Bayer will submit each assessment so that it will be received by the FDA on or before the due date.
Prescriber Enrollment and Agreement Form

In order to prescribe Adempas, prescribers must enroll in the Adempas REMS Program by completing this form.

Access this form online at www.adempasREMS.com, fax this form to 1-855-662-5200 or call the Adempas REMS Program at 1-855-4ADEMPAS (1-855-423-3672).

Prescriber Information (indicates required field)

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name*</td>
<td></td>
</tr>
<tr>
<td>Middle Initial</td>
<td></td>
</tr>
<tr>
<td>Last Name*</td>
<td></td>
</tr>
<tr>
<td>NPI*</td>
<td></td>
</tr>
<tr>
<td>Specialty*</td>
<td></td>
</tr>
<tr>
<td>Cardiology</td>
<td></td>
</tr>
<tr>
<td>Pulmonology</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

Credentials*: MD, DO, NP, PA, Other with prescriptive authority

Practice/Facility Name:

Address Line 1*:

Address Line 2:

City*:

State*:

Zip code*:

Phone*:

Fax*:

Email*:

Preferred Method of Contact: Phone, Email, Fax

Office Contact

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name</td>
<td></td>
</tr>
<tr>
<td>Last Name</td>
<td></td>
</tr>
<tr>
<td>Email* (required if Office Contact is provided)</td>
<td></td>
</tr>
</tbody>
</table>

Prescriber REMS Agreement

By signing below, you signify your understanding of the risks of Adempas treatment and your obligation as an Adempas prescriber to educate your female patients about the Adempas REMS Program, monitor them appropriately, and report any pregnancies to the Adempas REMS Program. Specifically, you attest to the following:

- I have read the Adempas Full Prescribing Information, Adempas Medication Guide and the Prescriber Guide for the Adempas REMS Program.
- I agree to enroll all female patients into the Adempas REMS Program.
- I will:
  - determine the reproductive potential status of all female patients using the definitions provided in the Prescriber Guide for the Adempas REMS Program.
  - advise all females that Adempas is only available through a restricted distribution program called the Adempas REMS Program.
  - counsel Females of Reproductive Potential (FRP) on Adempas risks, including serious birth defects, and review the Adempas Medication Guide and the Adempas REMS Guide for Females Who Can Get Pregnant with the patient.
  - counsel each FRP to immediately contact her healthcare provider if she misses a menstrual period or suspects pregnancy.
  - counsel the Pre-Pubertal Female (PPF) patient and/or her parent/guardian on the Adempas risks, including serious birth defects, and review the Adempas Medication Guide with the patient and parent/guardian.
  - verify the reproductive potential status annually for Pre-Pubertal Females who are at least 8 years of age and older.
  - counsel the PPF patient and/or her parent/guardian to contact her healthcare provider if she begins her menstrual period.
  - order and review pregnancy tests for FRPs prior to initiating Adempas treatment, monthly during treatment, and for one month after stopping treatment.
  - counsel each FRP to use reliable contraception during Adempas treatment, and for one month after stopping treatment, and discuss her medical options in the event of unprotected sexual intercourse or known or suspected contraceptive failure.
  - report any change in reproductive status by submitting an Adempas REMS Reproductive Potential Status Form within 10 business days of becoming aware of the change.
  - counsel female patients who fail to comply with the Adempas REMS Program requirements.
  - notify Bayer of any pregnancies at 1-888-842-2937 or send the information to DrugSafety.GPV.US@bayer.com.

Prescriber Signature*:

Date* (MM/DD/YYYY):

To report any adverse events, product technical complaints, medication errors or pregnancies associated with the use of Adempas, contact Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.

Phone: 1-855-4ADEMPAS (1-855-423-3672)  www.adempasREMS.com
Fax: 1-855-662-5200
AdEMPAS® REMS (Risk Evaluation And Mitigation Strategy)

Prescriber Guide for the Adempas REMS Program
# Table of Contents

I. Adempas REMS Program ................................................................. 3

II. Overview of the Adempas REMS Program ........................................ 4

III. Summary of Adempas REMS Program Requirements by Patient Category ........................................ 5

IV. Your Role in the Adempas REMS Program ......................................... 6

V. Contraceptive Options for Females of Reproductive Potential .................... 8

VI. Role of Certified Pharmacies .......................................................... 9

VII. The Adempas REMS Program Coordinating Center ................................ 10
I. Adempas REMS (Risk Evaluation and Mitigation Strategy) Program

IndICATIONS

Adempas® (riociguat) is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with:

- Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class.
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening.

Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominately patients with WHO functional class II–III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%).

RISK of TERATOGENICITY

Adempas is contraindicated in females who are pregnant. Adempas may cause fetal harm when administered to a pregnant woman. Adempas was consistently shown to have teratogenic effects when administered to animals. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. To prevent pregnancy, females of reproductive potential must use reliable contraception during treatment and for one month after stopping Adempas. Patients must not become pregnant while taking Adempas.

AdEMPAS REMS PRoGRAM

A Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage known or potential serious risks associated with a drug and is required by the US Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks.

Bayer Pharmaceuticals has worked with the FDA to develop the Adempas REMS Program to educate prescribers about the risk of teratogenicity. The REMS requires that females be enrolled in the Adempas REMS Program in order to receive Adempas.

The goals of the Adempas REMS Program are:

1. To inform prescribers, patients, and pharmacists about the serious risk of teratogenicity and safe-use conditions for Adempas

2. To minimize the risk of fetal exposure and adverse fetal outcomes in Females of Reproductive Potential prescribed Adempas
   a. Females who are pregnant must not be prescribed Adempas
   b. Females taking Adempas must not become pregnant
Because of the risk of teratogenicity, Adempas is available only through the Adempas REMS Program, which includes restricted distribution of Adempas.

The required components of the Adempas REMS Program are:

- Healthcare providers (prescribers) who prescribe Adempas must:
  - enroll in the program, and comply with the REMS requirements
  - educate and counsel Females of Reproductive Potential on the risks of Adempas, including the risk of serious birth defects
  - order and review pregnancy tests for Females of Reproductive Potential prior to initiation of treatment, monthly during treatment, and for one month after stopping treatment
  - report any change in a female’s reproductive status to the Adempas REMS Program

- Healthcare providers must enroll all female patients in the Adempas REMS Program after determining whether she is a Female of Reproductive Potential or a Female of Non-Reproductive Potential.

Definitions of Reproductive Potential Status

Females of Reproductive Potential
- Females of reproductive potential include girls who have entered puberty and all females who have a uterus and have not passed through menopause (as defined below).
- For the purposes of this REMS, puberty includes those girls who are at least Tanner Stage 3 and have not yet had a menses (premenarchal).

Females of Non-Reproductive Potential
- Pre-Pubertal Females: Females who are at Tanner Stages 1 and 2 are not considered to be of reproductive potential
- Post-Menopausal Females: Females who have passed through menopause (as defined below)

Definition of Menopause
- Menopause is defined as 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or post-surgical from bilateral oophorectomy.

- For Females of Reproductive Potential:
  - pregnancy must be ruled out prior to drug initiation and monthly during treatment
  - she must agree to be counseled on the requirements of the REMS program and the risks of Adempas
  - she must agree to be contacted by Bayer if she becomes pregnant either while on Adempas or within one month of treatment discontinuation

- Only certified outpatient pharmacies that agree to follow the Adempas REMS Program requirements via contract will dispense Adempas to outpatients.

- Only certified inpatient pharmacies that agree to follow the Adempas REMS Program requirements will stock Adempas for inpatient use.
III. Summary of the Adempas REMS Program

All prescribers must be enrolled in the Adempas REMS Program. To become enrolled, a healthcare provider must complete and submit an Adempas REMS Prescriber Enrollment and Agreement Form to the Adempas REMS Program agreeing to follow the Adempas REMS Program requirements.

All females must be enrolled in the Adempas REMS Program in order to receive Adempas. To become enrolled a patient must complete an Adempas Patient Enrollment and Consent Form with her prescriber. This form must be submitted to the Adempas REMS Program.

Prescribers must determine and document on the Adempas Patient Enrollment and Consent Form whether the patient is a Female of Reproductive Potential, or a Female of Non-Reproductive Potential (Pre-Pubertal Female or Post-Menopausal Female). This category must be documented on the Adempas Patient Enrollment and Consent Form. (See Section II for definitions of Reproductive Potential Status).

Based on whether the patient is a Female of Reproductive Potential, a Pre-Pubertal Female, or a Post-Menopausal Female, the prescriber must perform certain actions before initiating treatment, during treatment, and after the patient stops taking Adempas.

Summary of Adempas REMS Program Requirements by Patient Category

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Female of Reproductive Potential</th>
<th>Female of Non-Reproductive Potential</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-Pubertal</td>
<td>Post-Menopausal</td>
</tr>
<tr>
<td>Prescr ber enrolls female patients into the Adempas REMS Program</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Counseling with the Adempas REMS Guide for Females Who Can Get Pregnant</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Counseling with the Adempas Medication Guide, including the risk of teratogenicity</td>
<td>X</td>
<td>*</td>
</tr>
<tr>
<td>Prescr ber must order and review pregnancy tests prior to initiation of treatment, monthly during treatment, and for one month after stopping treatment</td>
<td>X</td>
<td>X*</td>
</tr>
<tr>
<td>Prescr ber must verify reproductive status annually by completing the Adempas REMS Reproductive Potential Status Form for females who are at least 8 years of age and older</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Prescr ber must complete the Adempas REMS Reproductive Potential Status Form upon becoming aware of any change in reproductive status within 10 business days of awareness</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

*Counsel Pre-Pubertal Female patient and/or parent/guardian

Reference ID: 3522688
Prescribers must complete the following steps in the Adempas REMS Program:

1. **Enroll in the Adempas REMS Program**
   - Prior to writing an Adempas prescription for a patient, a healthcare provider must enroll in the Adempas REMS Program.
     - Read the *Adempas Full Prescribing Information (PI)*, *Adempas Medication Guide*, and the *Prescriber Guide for the Adempas REMS Program* (this guide) to understand the risks of Adempas and the Adempas REMS Program requirements.
     - Agree to follow the Adempas REMS Program requirements by completing and submitting an *Adempas REMS Prescriber Enrollment and Agreement Form* to the Adempas REMS Program.
     - Receive an enrollment confirmation from the Adempas REMS Program verifying that certification has been completed. Prescribers can access the program materials at [www.adempasREMS.com](http://www.adempasREMS.com).

2. **determine the Reproductive Status of female Patients**
   (See definitions in Section II: Overview of the Adempas REMS Program).

3. **Educate and Counsel Patients**
   - For all females, prescribers must:
     - Advise the patient that Adempas is only available through a restricted distribution program called the Adempas REMS Program.
     - Educate and counsel patients about the risks of Adempas
       - For Females of Reproductive Potential, prescribers must:
         - Educate her about the risk of teratogenicity; the need to use reliable contraception during Adempas treatment and for one month following treatment discontinuation; and her medical options in the event of unprotected sexual intercourse or known or suspected contraception failure.
         - Advise the patient of the requirement for initial and monthly pregnancy tests to confirm they are not pregnant, so they can begin and continue to receive Adempas.
         - Provide ongoing counseling on the importance of using reliable contraception during Adempas treatment and for one month after stopping treatment.
         - Counsel her to immediately contact her healthcare provider if she misses a menstrual period or suspects she is pregnant.
• For Females of Non-Reproductive Potential, prescribers must:
  o Provide the *Adempas Medication Guide* to each Post-Menopausal Female and instruct her to read it.
  o For Pre-Pubertal Females, prescribers must:
    - Review with her and her parent/guardian the *Adempas Medication Guide*.
    - Educate her and her parent/guardian about the risk of teratogenicity.
    - Counsel her and her parent/guardian to immediately contact her healthcare provider if she gets her menstrual period.
  • Prescribers must counsel any patient who fails to comply with the program requirements.

4. Check Pregnancy Status (in females of Reproductive Potential)
   • Order a pregnancy test.
   • Review the pregnancy test results prior to the initiation of Adempas to ensure the result is negative.
   • Notify the patient of negative pregnancy test results prior to the initiation of Adempas.

5. Enroll female Patients in the Adempas REMS Program
   • All female patients must be enrolled in the Adempas REMS Program in order to receive Adempas.
   • Confirm that the patient has agreed to comply with the Adempas REMS Program requirements.
   • Complete with the patient the designated section of the *Adempas Patient Enrollment and Consent Form* and submit it to the Adempas REMS Program.

6. Monitor Patients
   • For Females of Reproductive Potential, prescribers must:
     o Order and review pregnancy tests monthly during treatment with Adempas and for one month after stopping treatment.
     o Notify the patient and Bayer if a patient’s pregnancy test is positive.
   • For Females of Non-Reproductive Potential, prescribers must:
     o Monitor patients for changes in reproductive status during treatment with Adempas.
     o Report any changes in reproductive status to the Adempas REMS Program by completing and submitting the *Adempas REMS Reproductive Potential Status Form* within 10 business days of becoming aware of the change.
     o Verify and report the reproductive status annually for each Pre-Pubertal Female who is at least 8 years of age and older by completing and submitting the *Adempas REMS Reproductive Status Potential Form*.

7. Report Pregnancies
   • Prescribers must also report any pregnancies associated with the use of Adempas to Bayer at 1-888-842-2937, or send the information to DrugSafety.
V. Contraceptive options for females of Reproductive Potential

Females of Reproductive Potential must use reliable contraception during treatment and for one month after stopping treatment. The table below indicates the acceptable contraception methods. The patient should be instructed to select one of the below options.

**Option 1**
- One method from this list:
  - Intrauterine system
  - LNG-20 IUS-progestosterone IUD
  - LNG-13.5 progesterone IUD
  - Standard intrauterine device
  - Copper T 380 A IUD
  - Tubal sterilization (tie, clip, band, burn)
  - Progesterone implant

**Option 2**
- One method from this list:
  - Estrogen and progesterone oral contraceptives ("the pill")
  - Estrogen and progesterone transdermal patch
  - Vaginal ring
  - Progesterone injection

**Option 3**
- One method from this list:
  - Diaphragm with spermicide
  - Cervical cap with spermicide

**Option 4**
- This method:
  - Partner's vasectomy

All Females of Reproductive Potential should undergo contraceptive counseling with either the prescriber or another designated healthcare provider trained in contraceptive counseling. Counseling should include a discussion about medical options in the event of unprotected sex or known or suspected contraceptive failure.

If pregnancy is suspected for any reason, a pregnancy test must be performed. The prescriber must notify the Adempas REMS Program of any pregnancies that occur during treatment or within one month after stopping treatment.

Reference ID: 3522688
VI. Role of Certified Pharmacies

Only a limited number of certified pharmacies will dispense Adempas for outpatients. Prior to dispensing Adempas to any female, the pharmacy will confirm that the female and the prescriber who wrote the prescription are enrolled in the Adempas REMS Program. If either the female or prescriber is not enrolled, Adempas will not be dispensed.

Females of Reproductive Potential and Pre-Pubertal Females will only be able to get a 30-day supply of Adempas at one time. The Adempas Medication Guide will be provided to all patients each time Adempas is dispensed.

Females of Reproductive Potential will be contacted each month by the pharmacy to arrange her dispensing of Adempas. The pharmacy will:

- Ask if she has had a pregnancy test within the last month
- Counsel her on the need to use reliable contraception during Adempas treatment and for one month after stopping treatment
- Counsel her to inform her prescriber immediately if she misses a menstrual period, suspects that she may be pregnant, or if her reproductive status changes

**Inpatient Pharmacy dispensing:**

Only inpatient pharmacies within institutions such as hospitals, long-term care facilities, prisons, and state psychiatric units that are certified in the Adempas REMS Program may stock Adempas for patients being treated in the inpatient setting. Inpatient pharmacies may not dispense more than a 15-day temporary supply of Adempas to any patient upon discharge from the healthcare facility. Bayer will ensure that if an inpatient pharmacy needs Adempas and is not certified in the Adempas REMS Program, the inpatient pharmacy can contact the Adempas REMS Program Coordinating Center for assistance in obtaining up to a 15-day supply of Adempas for a specific inpatient while initiating enrollment for certification.

VII. The Adempas REMS Program Coordinating Center

The Adempas REMS Program Coordinating Center will:

- Process the Adempas REMS Prescriber Enrollment and Agreement Form and the Adempas Patient Enrollment and Consent Form
- Answer questions for prescribers, patients and pharmacies, as they relate to the Adempas REMS Program
- Monitor compliance with the Adempas REMS Program requirements

The Adempas REMS Program Coordinating Center can be contacted at 1-855-4ADEMPAS (1-855-423-3672), Monday through Friday from 8:00 AM to 8:00 PM EST.
Adempas® REMS (Risk Evaluation and Mitigation Strategy) Guide for Females Who Can Get Pregnant
Table of Contents

I. What is Adempas? .................................................................................................................. 3
II. What are the serious risks of Adempas? ............................................................................. 3
III. What is the Adempas REMS Program? ............................................................................. 3
IV. Who is a female who is able to get pregnant? ................................................................. 4
V. How do I enroll in the Adempas REMS Program? ........................................................... 4
VI. What are my birth control options? .................................................................................. 5
VII. How will I get my Adempas medicine? .......................................................................... 6
VIII. What do I need to do while taking Adempas? ............................................................. 6
IX. Where can I look for more information about Adempas or the Adempas REMS Program? ................. 6
I. What is Adempas (riociguat)?

Adempas® is a prescription medicine used to treat adults with:

- **chronic thromboembolic pulmonary hypertension (CTEPH)**
  - treated with surgery but who continue to have high pulmonary blood pressure (persistent) or it comes back after surgery (recurrent), or
  - that cannot be treated with surgery.

CTEPH is a type of high blood pressure in the arteries of your lungs. Adempas can improve your ability to exercise and can help to improve some of your symptoms.

- **pulmonary arterial hypertension (PAH)**

PAH is a type of high blood pressure in the arteries of your lungs. Adempas can improve your ability to exercise, improve some of your symptoms, and help slow down the worsening of your physical condition.

It is unknown if Adempas is safe and effective in children.

II. What are the serious risks of Adempas?

Adempas may cause serious birth defects if taken while you are pregnant. You must not be pregnant when you start to take Adempas, become pregnant while taking Adempas, or become pregnant for one month after stopping Adempas.

III. What is the Adempas REMS (Risk Evaluation and Mitigation Strategy) Program?

The Adempas REMS is a program to tell patients and healthcare providers about the serious risks of birth defects while taking Adempas. This program is required by the Food and Drug Administration (FDA). All females must enroll in the Adempas REMS Program to receive Adempas. REMS stands for Risk Evaluation and Mitigation Strategy.

If you are a female who can get pregnant, to receive Adempas you must:

- Talk to your healthcare provider about the risks and benefits of Adempas
- Read:
  - The Adempas Medication Guide
  - The Adempas REMS Guide for Females Who Can Get Pregnant (this guide)
- Make sure you understand the risks and benefits of taking Adempas
- Have a pregnancy test before you start taking Adempas to be sure you are not pregnant
- Have a pregnancy test before you receive your refill each month
  - Your healthcare provider will order the pregnancy tests for you
  - Your pharmacy will call you every month to:
    - ask if you have taken a pregnancy test in the last month
    - remind you to use reliable birth control
  - Be sure you take your monthly pregnancy tests as ordered by your healthcare provider. You may not receive your Adempas refill on time if you do not take your monthly pregnancy tests
• Use reliable forms of birth control during Adempas treatment and for one month after stopping treatment with Adempas
  o Do not have unprotected sex.
  o Use the birth control options described on page 5 of this guide during your Adempas treatment and for one month after stopping your Adempas treatment.
  o Talk to your healthcare provider or pharmacist right away if you have unprotected sex, if you think your birth control has failed, or if you think you may be pregnant. If so, your healthcare provider may discuss medical options with you (e.g. emergency contraception). Do not wait until your next appointment to tell your healthcare provider if you miss your menstrual period or if you think you may be pregnant.
• Immediately notify your healthcare provider if you miss a menstrual period or suspect you are pregnant!

IV. Who is a female who is able to get pregnant?

You are considered a female who is able to get pregnant if you have had a menstrual period or any menstrual bleeding in the past 12 months or have not gone through menopause. Menopause means that you have not had any menstrual bleeding for 12 months.

Your healthcare provider gave you this guide and the Adempas Medication Guide to read because you are taking Adempas and may be able to get pregnant. Talk to your healthcare provider if you have any questions about being a female who is able to get pregnant or about taking Adempas.

V. How do I enroll in the Adempas REMS Program?

• Talk with your healthcare provider to make sure that Adempas is right for you
• Read the Adempas Medication Guide (comes with your medicine) and the Adempas REMS Guide for Females Who Can Get Pregnant (this guide)
• Ask your healthcare provider any questions that you have about Adempas and the Adempas REMS Program
• Agree to all the requirements of the Adempas REMS Program
• Complete and sign the Adempas Patient Enrollment and Consent Form with your healthcare provider

To enroll you in the Adempas REMS Program, your healthcare provider will send in your Adempas Patient Enrollment and Consent Form. The Adempas REMS Program will keep your information in a secure and validated database.
VI. What are my birth control options?

Your healthcare provider will talk to you about your options for reliable birth control. Use the tables below to help decide what birth control option is best for you.

**OPTION 1**

One method from this list:
- Intrauterine system
- LNG-20 IUS-progesterone IUD
- LNG-13.5 progesterone IUD
- Standard intrauterine device
- Copper T 380 A IUD
- Tubal sterilization (tie, clip, band, burn)
- Progesterone implant

**OPTION 2**

One method from this list:
- Estrogen and progesterone oral contraceptives ("the pill")
- Estrogen and progesterone transdermal patch
- Vaginal ring
- Progesterone injection

**OPTION 3**

One method from this list:
- Diaphragm with spermicide
- Cervical cap with spermicide

**OPTION 4**

This method:
- Partner's vasectomy

If you can get pregnant, do not have unprotected sex. Talk to your healthcare provider or pharmacist right away if you have unprotected sex or if you think your birth control has failed. If so, your healthcare provider may discuss medical options with you (e.g., emergency contraception). Tell your healthcare provider right away if you miss a menstrual period or if you think you may be pregnant.
VII. How will I get my Adempas medicine?

Adempas is not available at your local pharmacy. You can only get it through a certified pharmacy, sometimes called a “specialty” pharmacy. After you enroll, your prescription will be sent to a certified pharmacy.

Before the pharmacy sends your prescription, they will call to confirm that you had a pregnancy test taken in the last month.

The pharmacy will send Adempas directly to your home or where you tell them to send it.

- If you did not complete your pregnancy test for that month, your Adempas prescription or refill will be delayed.
- The pharmacy will remind you to use reliable birth control during treatment with Adempas and for one month after stopping treatment with Adempas.

The pharmacy will also:

- Handle your insurance claims
- Answer questions that you have about Adempas

VIII. What do I need to do while taking Adempas?

- Use reliable birth control during treatment with Adempas and for one month after stopping Adempas.
- Have a pregnancy test taken every month.
- Tell your healthcare provider right away if you:
  - have unprotected sex
  - think that your birth control failed
  - miss a menstrual period
  - think you may be pregnant

IX. Where can I find more information about Adempas and the Adempas REMS Program?

- Get the Adempas Medication Guide from your healthcare provider or nurse. It will also come with your medicine.
- Talk with your healthcare provider, nurse, or pharmacist about Adempas.
- For questions about getting your Adempas prescription filled or being in the Adempas REMS Program, please call the Adempas REMS Program Coordinating Center at 1-855-4ADEMPAS (1-855-423-3672).
Adempas Patient Enrollment and Consent Form

Access this form online at www.adempasREMS.com, or fax this form to the Adempas Program at 1-855-662-5200

1 Patient Information (* indicates required field)
First Name*: Middle Initial Last Name*: Birthdate (MM/DD/YYYY): Gender*: Male Female
Address Line 1*: Address Line 2:
City*: State*: Zip code*: Preferred Phone*: Can we leave a message on this phone? Yes No Preferred Time to Contact: Day Evening
Alternate Phone: Email:
Alternate Contact Name: Phone: Relationship:

Does the patient have medical insurance? Yes No Does the patient have prescription coverage? Yes No *Provide all relevant patient insurance information, including drug benefits (front and back) with this form.

2 Female Patient Agreement
For all females: I acknowledge that I understand Adempas is only available through a restricted distribution program under an FDA-required Risk Evaluation and Mitigation Strategy (REMS).
For females who can get pregnant: I acknowledge that I have been counseled on the risks of Adempas, including the risk of serious birth defects.
I have read the Adempas Medication Guide and the Adempas REMS Guide for females who can get pregnant. I understand that I will be contacted by Bayer and its agents and contractors to receive counseling on the risk of serious birth defects, the need to use reliable contraception during Adempas treatment and for one month after stopping Adempas treatment, and the importance of not becoming pregnant and for one month after stopping Adempas. I agree to be counseled each month by the pharmacist on the need to use reliable contraception during Adempas treatment and for one month after stopping Adempas. I understand that I must immediately contact my healthcare provider if I miss a menstrual period or suspect that I am pregnant and that I may be contacted by Bayer and its agents and contractors to obtain information about my pregnancy.
For pre-pubertal females: I acknowledge that I have been counseled on the risks of Adempas, including the risk of serious birth defects, and that I have read the Adempas Medication Guide. I understand that I must immediately contact my healthcare provider if I get my menstrual period.
For post-menopausal females: I acknowledge that I have received and read the Adempas Medication Guide.

3 Prescriber Information (* indicates required field)
First Name*: Last Name*: NPI:
Practice/Facility Name (where you see this patient):
Address Line 1*: Address Line 2:
City: State: Zip code: Phone:

State License #:

4 PreScription (* indicates required field) Prescription is only valid if faxed. Note: NY Prescribers please submit prescription on an original NY State prescription blank, for all other States, if not faxed, must be on State-specific blank if applicable for your state.

Initial dose*: Titrination schedule:
- Adempas 1 mg tablet by mouth three times a day
- Adempas 0.5 mg tablet by mouth three times a day

Directions: If systolic blood pressure is >95 mmHg and there are no signs/symptoms of hypotension, increase the dose by 0.5 mg 3 times per day at intervals no sooner than 2 weeks to the highest tolerated dosage up to a maximum of 2.5 mg 3 times per day.

Other special instructions:

Deliver to: Patient Home (address listed above) Prescriber Office (address listed above)

5 Prescriber Authorization
For female patients, please indicate the patient's current reproductive status below (please see definitions of these terms on the following page)

Female of Reproductive Potential
If this patient is a Female of Reproductive Potential, has a pregnancy test been completed prior to prescribing Adempas? Yes No
Female of Non-Reproductive Potential (choose one below)
- Pre-Pubertal Female
- Female of Non-Reproductive Potential

I certify that the above therapy is medically necessary and that the information provided is accurate to the best of my knowledge. I certify that for female patients, I have provided the appropriate counseling and Adempas REMS materials, and I will continue to fulfill my obligations under the Adempas REMS Program. I appoint the Adempas REMS Program, on my behalf, to convey this prescription to the dispensing pharmacy. I understand that I may not delegate signature authority. I authorize the Lab Coordination Program to order laboratory tests on my behalf for patients enrolled in the Adempas REMS Program based on the orders I will provide. I understand that it is not the responsibility of the Lab Coordination Program to review or interpret laboratory test results or to provide patient care or patient counseling.

Required Prescriber Signature: Date*

Phone: 1-855-4ADEMPAS (1-855-423-3672) www.adempasREMS.com Fax: 1-855-662-5200
Reference ID: 3522688
5 Prescriber Authorization (continued)

Definitions:
Females of Reproductive Potential
- Females of reproductive potential include girls who have entered puberty and all females who have a uterus and have not passed through menopause (as defined below).
- For the purposes of this REMS, puberty includes those girls who are at least Tanner Stage 3 and have not yet had a menses (premenarchal).

Females of Non-Reproductive Potential
- Pre-Pubertal Females: Females who are at Tanner Stages 1 and 2 are not considered to be of reproductive potential.
- Post-Menopausal Females: Females who have passed through menopause (as defined below).

Definition of Menopause
- Menopause is defined as 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or post-surgical from bilateral oophorectomy.

Prescriber Obligations under the Adempas REMS Program

For All Females
- I acknowledge that I have counseled the patient (and parent/guardian when appropriate) that Adempas is only available through a restricted distribution program under an FDA required REMS.
- I will evaluate the patient and agree to document any change in reproductive status by completing and submitting an Adempas REMS Reproductive Potential Status Form within 10 business days of becoming aware of the change.

For Females of Reproductive Potential
- I acknowledge that I have counseled the patient (and parent/guardian when appropriate) on the risks of Adempas, including the risk of serious birth defects, and that I have reviewed the Adempas Medication Guide and the Adempas REMS Guide for Females Who Can Get Pregnant with the patient (and parent/guardian when appropriate).
- I will order and review pregnancy tests prior to initiation of Adempas treatment, monthly during treatment, and for one month after stopping treatment in accordance with the Adempas REMS Program.

For Pre-Pubertal Females
- I acknowledge that I have counseled the patient and parent/guardian on the risks of Adempas, including the risk of serious birth defects, and that I have reviewed the Adempas Medication Guide with the patient and parent/guardian.
- I will evaluate the patient’s reproductive status, verify reproductive status annually for Pre-Pubertal Females who are at least 8 years of age and older, and agree to report any change in reproductive status on an Adempas REMS Reproductive Potential Status Form within 10 business days of becoming aware of the change.

6 Statement of Medical Necessity (* indicates required field)
The following does not suggest approved uses or indications.

Diagnosis*:
- Chronic thromboembolic pulmonary hypertension
- Pulmonary arterial hypertension
- Inoperable
- After surgical treatment

Pulmonary hypertension status*: Newly diagnosed  Previously diagnosed

ICD-9 Code*:
- 416.0 (Primary pulmonary hypertension)
- 416.6 (Other chronic pulmonary heart diseases, e.g. pulmonary hypertension, secondary)
- 416.9 (Chronic pulmonary heart disease, unspecified)
- Other (specify):__________

7 Written Permission to Share Information

I authorize my healthcare providers, pharmacies, and health plan insurers to share my name, address, and phone number, along with my prescription, treatment and insurance information relating to my use or need for Adempas with Bayer and its agents and contractors (collectively “Bayer”). I understand that certain healthcare providers, such as my pharmacies, will receive payment from Bayer in connection with the disclosure of my information as I allow through this authorization.

I allow my information to be shared with Bayer so that it may: 1) communicate with me, my healthcare providers and health plans about my medical care; 2) provide support services, including providing Adempas to me and planning laboratory testing for me; 3) learn how well Adempas, the Adempas REMS, or Adempas Program is working; and 4) contact me so that I may receive educational materials about Adempas, the Adempas REMS, or the Adempas Program.

This authorization expires at the end of my participation in the Adempas Program or 10 years after the date I sign it if earlier. I can cancel this authorization earlier by writing to 200 Pinecrest Plaza, Morgantown, WV 26505. The cancellation will not apply to information already released by my healthcare providers, pharmacies, and health plans and before they learn about my cancellation. Once my information is disclosed to Bayer it will no longer be protected by federal privacy laws and my information may be given out (re-disclosed) by Bayer. However, I understand that Bayer will make every effort to keep my information confidential and only use and share it for the purposes stated in this authorization. I may refuse to sign this form, and if I do, this refusal will not affect my treatment, payment for treatment, enrollment in a health plan, or eligibility for benefits. However, if I refuse, I know that this means I may no longer be able to receive assistance from the Adempas Program. I understand I am entitled to receive a copy of this

REQUIRED FOR ALL PATIENTS

Patient or Parent/Guardian Signature*:

Date*:

8 Submit this form online at www.adempasREMS.com or fax this form to 1-855-242-5200

To report any adverse events, product technical complaints, medication errors or pregnancies associated with the use of Adempas, contact Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.

Phone: 1-855-4ADEMPAS (1-855-423-3672)  www.adempasREMS.com  Fax: 1-855-662-5200

Reference ID: 3522688
Reproductive Potential Status Form

All females must be enrolled in the Adempas REMS Program in order to receive Adempas.

Complete this form to:
1) Change the reproductive status of any female patient, or
2) Perform the annual verification of reproductive status for Pre-Pubertal Females, 8 years of age or older

Access this form online at www.adempasREMS.com or fax this form to the Adempas Program at 1-855-662-5200 and to the patient’s certified pharmacy.

<table>
<thead>
<tr>
<th>Patient Information (*) indicates required field</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name*:</td>
</tr>
<tr>
<td>Address Line 1*:</td>
</tr>
<tr>
<td>City*:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prescriber Information (*) indicates required field</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name*:</td>
</tr>
<tr>
<td>Practice/Facility Name:</td>
</tr>
<tr>
<td>Address Line 1*:</td>
</tr>
<tr>
<td>City:</td>
</tr>
</tbody>
</table>

Definitions of Reproductive Potential Status

Females of Reproductive Potential
- Females of reproductive potential include girls who have entered puberty and all females who have a uterus and have not passed through menopause (as defined below).
- For the purposes of this REMS, puberty includes those girls who are at least Tanner Stage 3 and have not yet had a menses (premenarchal).

Females of Non-Reproductive Potential
- Pre-Pubertal Females: Females who are at Tanner Stages 1 and 2 are not considered to be of reproductive potential.
- Post-Menopausal Females: Females who have passed through menopause (as defined below).

Definition of Menopause
- Menopause is defined as 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or post-surgical from bilateral oophorectomy.

Please select the most appropriate reason for submitting this form*

Annual Verification
- Patient remains a Pre-Pubertal Female (8 years of age or older)

Change in Status (Check ONE box)
- Patient is a Female of Reproductive Potential because:
  - Patient is a female who has entered puberty, or
  - Patient was previously misclassified

- Patient is a Female of Non-Reproductive Potential because:
  - Patient is Post-Menopausal, or
  - Patient was previously misclassified, and is now Pre-Pubertal, or
  - Patient was previously misclassified, and is now Post-Menopausal

By signing, I certify that the patient’s reproductive potential status and reason for submitting this form are accurately noted above. I certify that I will follow the REMS requirements while treating this patient.

** REQUIRED **

| Prescriber Signature*: | Date* (MM/DD/YYYY): |

To report any adverse events, product technical complaints, medication errors or pregnancies associated with the use of Adempas, contact Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.

Phone: 1-855-4ADEMPAS (1-855-423-3672) www.adempasREMS.com
Fax: 1-855-662-5200
Welcome to the Adempas REMS (Risk Evaluation and Mitigation Strategy) Program

The Adempas REMS is a program to tell patients and healthcare providers about the serious risks of birth defects while taking Adempas. This program is required by the Food and Drug Administration (FDA). All females must enroll in the Adempas REMS Program to receive Adempas. REMS stands for Risk Evaluation and Mitigation Strategy.

Bayer Pharmaceuticals has worked with the FDA to develop the Adempas REMS Program to educate prescribers and patients about the risk of teratogenicity. The REMS will require that females agree to follow the REMS requirements to be enrolled in the Adempas REMS Program in order to receive Adempas® (riociguat).

Adempas REMS Program Overview

- Females must not be pregnant when they start taking Adempas, become pregnant during treatment, or become pregnant for one month after stopping Adempas treatment.
- All healthcare providers must enroll in the Adempas REMS Program and agree to the REMS requirements to prescribe Adempas.
- All female patients must enroll in the Adempas REMS Program and agree to the REMS requirements to receive Adempas.
- A limited number of certified pharmacies will dispense Adempas for outpatients. They must enroll in the Adempas REMS Program and agree to the REMS requirements to provide Adempas for outpatient use.
- Inpatient pharmacies must enroll in the Adempas REMS Program and agree to the REMS requirements to stock Adempas for inpatient use.

Click below to learn more about the Adempas REMS Program


INDICATIONS

- Adempas is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class.
- Adempas is indicated for the treatment of adults with pulmonary arterial hypertension (PAH) (WHO Group 1), to improve exercise capacity, improve WHO functional class, and to delay clinical worsening.

Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists or prostanooids. Studies establishing effectiveness included predominately patients with WHO functional class II-III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%).
Due to the risk of pregnancy only through the Adempas REMS (Risk Evaluation and Mitigation Strategy) Program.

The goals of the Adempas REMS Program are:

1. To inform prescribers, patients, and pharmacists about the serious risk of teratogenicity and safe-use conditions for Adempas
2. To minimize the risk of fetal exposure and adverse fetal outcomes in Females of Reproductive Potential prescribed Adempas
   a. Females who are pregnant must not be prescribed Adempas
   b. Females taking Adempas must not become pregnant

In order to prescribe and receive Adempas, prescribers and females must enroll in the Adempas REMS Program and agree to comply with the requirements of the program.

Only a limited number of certified pharmacies will dispense Adempas to outpatients.

To enroll in the Adempas REMS Program, prescribers must:

- Read the Adempas Full Prescribing Information (PI), Adempas Medication Guide, and the Prescriber Guide for the Adempas REMS Program
- Agree to follow the REMS requirements by completing and submitting an Adempas REMS Prescriber Enrollment and Agreement Form to the Adempas REMS Program
- Complete the Adempas REMS Prescriber Enrollment and Agreement Form:
  - Online
  - By fax at 1-355-662-5200
  - By calling the Adempas REMS Program at 1-855-4ADEMPAS (1-855-423-6722)
- Receive an enrollment confirmation from the Adempas REMS Program verifying that enrollment has been completed
**Prescriber Roles and Responsibilities**

1. Enroll in the Adempas REMS Program
   - Prior to writing an Adempas prescription for a patient, a healthcare provider must enroll in the Adempas REMS Program.
   - Follow the Adempas REMS Program—a mandatory electronic program—online. The Program consists of two main components:
     - The Prescriber Enrolment and Consent Form, which is available for download.
     - The Prescriber Education and Agreement Form, which must be completed and signed.

2. Determine the reproductive potential status of female patients
   - **Females of Reproductive Potential**
     - Female patients of reproductive potential receive the following medication:
       - Women who have not had a hysterectomy and who have not passed the menstrual cycle by 50 years of age.
   - **Females of Non-Reproductive Potential**
     - Women who have had a hysterectomy and who have not passed the menopause by 50 years of age.

3. Educate and Counsel Patients
   - Educate and counsel patients regarding the risks of Adempas.
   - Refer patients to the Adempas REMS Program.
   - Refer patients to the Adempas Patient Information Guide for the additional information regarding the use of Adempas.

4. Check Pregnancy Status (in Females of Reproductive Potential)
   - Inform your patient.
   - Refer to the Adempas Pregnancy Information Guide.
   - Implement the Adempas Pregnancy Risk Mitigation Plan.

5. Enroll Female Patients in the Adempas REMS Program
   - All female patients must be enrolled in the Adempas REMS Program in order to receive Adempas.
   - Confirm that all patients have agreed to comply with the Adempas REMS Program requirements.

6. Monitor Patients
   - Patient monitoring should be performed as follows:
     - Monitor all patients for changes in reproductive status during treatment with Adempas.
     - Patient monitoring should be performed as follows:
       - Monitor all patients for changes in reproductive status during treatment with Adempas.

7. Report Pregnancies
   - Pharmacies must immediately notify the Adempas REMS Program of any pregnancy within 48 hours of notification.
INFORMATION FOR FEMALE PATIENTS

Adempas® is a prescription medicine to treat adults with:

- chronic thromboembolic pulmonary hypertension (CTEPH)
  - treated with surgery but who continue to have high pulmonary blood pressure (persistent) or it comes back after surgery (recurrent), or
  - that cannot be treated with surgery
CTEPH is a type of high blood pressure in the arteries of your lungs caused by blood clots that narrow or block blood flow. Adempas can improve your ability to exercise and help to improve some of your symptoms.

- pulmonary arterial hypertension (PAH)
PAH is a type of high blood pressure in the arteries of your lungs. Adempas can improve your ability to exercise, improve some of your symptoms, and help slow down the worsening of your physical condition.

It is unknown if Adempas is safe and effective in children.

Because of the serious risks of birth defects while taking Adempas, the FDA (Food and Drug Administration) requires a program called REMS. REMS stands for Risk Evaluation and Mitigation Strategy. The purpose of this program is to make sure that patients and prescribers understand the risks. All females must enroll in the Adempas REMS Program to receive Adempas.

If you are a female who can get pregnant, to receive Adempas you must:

- Talk to your healthcare provider about the risks and benefits of Adempas.
- Read:
  - The Adempas Medication Guide, Spanish Adempas Medication Guide and
- Have a pregnancy test before you start taking Adempas
- Have a pregnancy test before you receive your refill each month
- Use reliable forms of birth control during Adempas treatment and for one month after stopping treatment with Adempas
- Immediately notify your healthcare provider if you miss a menstrual period or suspect you are pregnant

For more information on Adempas, the Adempas REMS Program, and reliable forms of birth control, download the Adempas REMS Guide for Females Who Can Get Pregnant, Spanish Adempas REMS Guide for Females Who Can Get Pregnant.

To learn more about the serious risks associated with Adempas, please refer to the Full Prescribing Information including Boxed Warning, Spanish Full Prescribing Information, Adempas Medication Guide and the Spanish Adempas Medication Guide.
CERTIFIED OUTPATIENT PHARMACY OVERVIEW

Due to the risk of teratogenicity, Adempas is available only through the Adempas REMS Program. Adempas will be dispensed to outpatients by a limited number of certified pharmacies. The pharmacy will confirm that the prescriber who wrote the prescription is enrolled, and if the patient is a female that she is enrolled in the Adempas REMS Program. If either the female or prescriber is not enrolled, Adempas will not be dispensed.

For Females of Reproductive Potential, pharmacies will:

- Ask the patient if she has had a pregnancy test within the last month
- Counsel her on the need to use reliable contraception during Adempas treatment and for one month after stopping treatment
- Counsel her to inform her prescriber immediately if she misses a menstrual period or suspects that she may be pregnant or if her reproductive status changes

Females of Reproductive Potential and Pre-Pubertal Females will only be able to get a 30 day supply of Adempas at one time. The Adempas Medication Guide will be provided to all patients each time Adempas is dispensed.

To learn more about the serious risks associated with Adempas, please refer to the Full Prescribing Information including Boxed Warning, Spanish Full Prescribing Information, Adempas Medication Guide, Spanish Adempas Medication Guide and the Prescriber Guide for the Adempas REMS Program.
CERTIFIED INPATIENT PHARMACY OVERVIEW

Due to the risk of teratogenicity, Adempas is available only through the Adempas REMS Program.

In order to stock Adempas, inpatient pharmacies must enroll and be certified in the Adempas REMS Program.

Inpatient pharmacies must agree to follow the REMS requirements, including:

- establish systems, protocols, or other measures to ensure the REMS requirements are met.
- dispense only after contacting the Adempas REMS Program Coordinating Center to confirm the REMS requirements are met.
- not transfer Adempas to any pharmacy, practitioner or healthcare setting not certified by the Adempas REMS Program.
- confirm the inpatient is under the care of a healthcare provider certified in the Adempas REMS Program.
- develop a process to track compliance with the conditions above and provide information about its compliance to Bayer upon request.
- report any pregnancies associated with the use of Adempas to Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.
- dispense no more than a 15-day temporary supply of Adempas to any patient upon discharge from the healthcare facility.

To be certified in the Adempas REMS Program, an authorized representative of the inpatient pharmacy must:

- Agree to follow the REMS requirements by completing and submitting an Adempas REMS Inpatient Pharmacy Enrollment Form to the Adempas REMS Program.
  - Authorized representatives can complete the Adempas REMS Inpatient Pharmacy Enrollment Form:
    - Online
    - By fax at 1-855-662-5200
    - By calling the Adempas REMS Program at 1-855-4ADEMPAS (1-855-423-3672)
- If an inpatient pharmacy needs Adempas and is not certified in the Adempas REMS Program, the inpatient pharmacy can contact the Adempas REMS Program Coordinating Center at 1-855-4ADEMPAS (1-855-423-3672) for assistance in obtaining up to a 15-day supply of Adempas for a specific inpatient while initiating enrollment.

Login is available for enrolled prescribers and office contacts designated by prescribers only.

To learn more about the serious risks associated with Adempas, please refer to the Full Prescribing Information including Boxed Warning, Spanish Full Prescribing Information, Adempas Medication Guide, Spanish Adempas Medication Guide, and the Prescriber Guide for the Adempas REMS Program.
Phone: 1-855-4ADEMPAS (1-855-423-3672)
Fax: 1-855-662-5200

Hours of Operation: Monday- Friday 8:00 AM - 8:00 PM Eastern

To report any adverse events, product technical complaints, medication errors, or pregnancies associated with the use of Adempas, contact:
Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.

To learn more about the serious risks associated with Adempas, please refer to the Full Prescribing Information including Boxed Warning, Spanish Full Prescribing Information, Adempas Medication Guide, Spanish Adempas Medication Guide, and the Prescriber Guide for the Adempas REMS Program.
Inpatient Pharmacy Enrollment Form

Due to a risk of fetal exposure and adverse fetal outcomes in females of reproductive potential prescribed Adempas, Adempas is available only through the Adempas REMS Program. The Adempas REMS Program is a component of a Risk Evaluation and Mitigation Strategy (REMS). In order for inpatients to receive Adempas, females as well as inpatient pharmacies that wish to stock this product, must enroll in the Adempas REMS Program and agree to comply with the requirements of the program.

Access this form online at www.adempasREMS.com, fax this form to 1-855-662-5200 or call the Adempas REMS Program at 1-855-4ADEMPAS (1-855-423-3672).

Inpatient Pharmacy Information (* indicates required field)

Type of facility: □ Hospital □ Long-term Care Facility □ Prison □ Other _____________________________ NPI:*

Facility Name:*  
Address Line 1:*  
Address Line 2:  
City:*  
State:*  
Zip code:*  
Phone:*  
Ship To Information (* indicates required field)

Ship To Address: □ Same as above  
Ship To Contact Name:*  
Address Line 1:*  
Address Line 2:  
City:*  
State:*  
Zip code:*  
Phone:*  
Fax:*  
Authorized Representative Information (* indicates required field)

First Name:*  
Middle Initial:*  
Last Name:*  
Position/Title: □ Hospital Pharmacist □ Head of P & T Committee □ Other Title  
Phone:*  
Fax:*  
Email:*  
Inpatient Pharmacy Acknowledgement

This inpatient pharmacy will:
- establish systems, protocols, or other measures to ensure the REMS requirements are met.
- dispense only after contacting the Adempas REMS Program Coordinating Center to confirm the REMS requirements are met.
- not transfer Adempas to any pharmacy, practitioner, or healthcare setting not certified by the Adempas REMS Program.
- confirm the inpatient is under the care of a healthcare provider certified in the Adempas REMS Program.
- develop a process to track compliance with the conditions above and provide information about its compliance to Bayer upon request.
- report any pregnancies associated with the use of Adempas to Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.
- dispense no more than a 15-day temporary supply of Adempas to any patient upon discharge from the healthcare facility.

Note: If your inpatient pharmacy needs Adempas and is not certified in the Adempas REMS Program, contact the Adempas REMS Program Coordinating Center at 1-855-4ADEMPAS (1-855-423-3672) for assistance in obtaining up to a 15-day supply of Adempas for a specific inpatient while initiating enrollment.

REQUIRED  
Authorized Representative Signature*:  
Date* (MM/DD/YYYY):  

To report any adverse events, product technical complaints, medication errors or pregnancies associated with the use of Adempas, contact Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.

Phone: 1-855-4ADEMPAS (1-855-423-3672)  
Fax: 1-855-662-5200  
www.adempasREMS.com
Adempas Patient Enrollment and Consent  

For V.A. Use Only

1 Patient Information  (* indicates required field)

<table>
<thead>
<tr>
<th>First Name*:</th>
<th>Middle Initial</th>
<th>Last Name*:</th>
<th>Birthdate*(MM/DD/YYYY):</th>
<th>Gender*:</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Address Line 1*:</th>
<th>Address Line 2:</th>
</tr>
</thead>
<tbody>
<tr>
<td>State*:</td>
<td>Zip code*:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Preferred Phone*:</th>
<th>Preferred Time to Contact:</th>
<th>Day*</th>
<th>Evening</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>City*:</th>
<th>State*:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Zip code*:</th>
<th>Phone*:</th>
</tr>
</thead>
</table>

V.A. PATIENT-NO INSURANCE REQUIRED

2 Female Patient Agreement

For all Females: I acknowledge that I understand that Adempas is only available through a restricted distribution program under an FDA-required Risk Evaluation and Mitigation Strategy (REMS).

For Females Who Can Get Pregnant: I acknowledge that I have been counseled on the risks of Adempas, including the risk of serious birth defects. I have read the Adempas Medication Guide and the Adempas REMS Guide for Females Who Can Get Pregnant. I understand that I will be contacted by Bayer and/or its agents and contractors to receive counseling on the risk of serious birth defects, the need to use reliable contraception during Adempas treatment and for one month after stopping Adempas treatment, and the importance of not becoming pregnant; and to ensure that I have completed pregnancy testing before I started Adempas, monthly before each refill, and for one month after stopping Adempas. I agree to be counseled each month by the pharmacy on the need to use reliable contraception during Adempas treatment and for one month after stopping Adempas. I understand that I must immediately contact my healthcare provider if I miss a menstrual period or suspect that I am pregnant and that I may be contacted by Bayer and/or its agents and contractors to obtain information about my pregnancy.

For Pre-Pubertal Females: I acknowledge that I have been counseled on the risks of Adempas, including the risk of serious birth defects, and that I have read the Adempas Medication Guide. I understand that I must immediately contact my healthcare provider if I get my menstrual period.

For Post-Menopausal Females: I acknowledge that I have received and read the Adempas Medication Guide

3 Prescriber Information  (* indicates required field)

<table>
<thead>
<tr>
<th>First Name*:</th>
<th>Last Name*:</th>
<th>NPI*:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Address Line 1*:</th>
<th>Address Line 2:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>City*:</th>
<th>State*:</th>
<th>Zip code*:</th>
<th>Phone*:</th>
</tr>
</thead>
</table>

4 Prescription  (* indicates required field)  

Prescription is only valid if faxed. Note: NY Prescribers please submit prescription on an original NY State prescription blank, for all other States, if not faxed, must be on State specific blank if applicable for your State.

<table>
<thead>
<tr>
<th>Initial dose*:</th>
<th>Titration schedule:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ Adempas 1 mg tablet by mouth three times a day</td>
<td>□ Based on patient’s response per clinical evaluation of the physician or the nurse in consultation with the physician, the pharmacy is to provide the Adempas strength to accommodate titration needs of therapy.</td>
</tr>
<tr>
<td>□ Adempas 0.5 mg tablet by mouth three times a day</td>
<td>Strength: Adempas 0.5 mg Adempas 1 mg Adempas 1.5 mg Adempas 2 mg Adempas 2.5 mg</td>
</tr>
<tr>
<td>□ 30 day supply</td>
<td>Directions: If systolic blood pressure is &gt;95 mmHg and there are no signs/symptoms of hypotension, up titrate by 0.5 mg 3 times per day at intervals no sooner than 2 weeks to the highest tolerated dosage up to a maximum of 2.5 mg 3 times per day. If at any time, the patient has symptoms of hypotension, decrease dose by 0.5 mg 3 times daily. The established individual dose should be maintained.</td>
</tr>
<tr>
<td>□ Other*</td>
<td>□ Other special instructions:</td>
</tr>
</tbody>
</table>

Deliver to: □ Patient Home (address listed above) □ V.A. Pharmacy (address listed below)

<table>
<thead>
<tr>
<th>V.A. Pharmacy Name:</th>
<th>Department:</th>
<th>Attention:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Address Line 1:</th>
<th>Address Line 2:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>City*:</th>
<th>State*:</th>
<th>Zip code*:</th>
<th>Phone*:</th>
</tr>
</thead>
</table>

5 Prescriber Authorization

For female patients, please indicate the patient’s current reproductive status below (please see definitions of these terms on the following page)

Female of Reproductive Potential

If this patient is a Female of Reproductive Potential, has a pregnancy test been completed prior to prescr bing Adempas? □ Yes  □ No

Female of Non-Reproductive Potential (choose one below)

□ Pre-Pubertal Female  □ Post-Menopausal Female

I certify that the above therapy is medically necessary and that the information provided is accurate to the best of my knowledge. I certify that for female patients, I have provided the appropriate counseling and Adempas REMS materials, and I will continue to fulfill my obligations under the Adempas REMS Program. I appoint the Adempas REMS Program, on my behalf, to convey this prescription to the dispensing pharmacy. I understand that I may not delegate signature authority.

<table>
<thead>
<tr>
<th>Prescriber Signature*:</th>
<th>Date*:</th>
</tr>
</thead>
</table>

Phone: 1-855-4ADEMPAS (1-855-423-3672)  www.adempasREMS.com  Fax: 1-855-662-5200

Reference ID: 3522688
5 Prescriber Authorization (continued)

Definitions:
- Females of Reproductive Potential
  - Females of reproductive potential include girls who have entered puberty and all females who have a uterus and have not passed through menopause (as defined below).
  - For the purposes of this REMS, puberty includes those girls who are at least Tanner Stage 3 and have not yet had a menses (premenarchal).
- Females of Non-Reproductive Potential
  - Pre-Pubertal Females: Females who are at Tanner Stages 1 and 2 are not considered to be of reproductive potential.
  - Post-Menopausal Females: Females who have passed through menopause (as defined below).

Definition of Menopause
- Menopause is defined as 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or post-surgical from bilateral oophorectomy.

Prescriber Obligations under the Adempas REMS Program

For All Females
- I acknowledge that I have counseled the patient (and parent/guardian when appropriate) that Adempas is only available through a restricted distribution program under an FDA-required REMS.
- I will evaluate the patient and agree to document any change in reproductive status by completing and submitting an Adempas REMS Reproductive Potential Status Form within 10 business days of becoming aware of the change.

For Females of Reproductive Potential
- I acknowledge that I have counseled the patient (and parent/guardian when appropriate) on the risks of Adempas, including the risk of serious birth defects, and that I have reviewed the Adempas Medication Guide and the Adempas REMS Guide for Females Who Can Get Pregnant with the patient (and parent/guardian when appropriate).
- I will order and review pregnancy tests prior to initiation of Adempas treatment, monthly during treatment, and for one month after stopping treatment in accordance with the Adempas REMS Program.

For Pre-Pubertal Females
- I acknowledge that I have counseled the patient and parent/guardian on the risks of Adempas, including the risk of serious birth defects, and that I have reviewed the Adempas Medication Guide with the patient and parent/guardian.
- I will evaluate the patient’s reproductive status, verify reproductive status annually for Pre-Pubertal Females who are at least 8 years of age and older, and agree to report any change in reproductive status on an Adempas REMS Reproductive Potential Status Form within 10 business days of becoming aware of the change.

6 Statement of Medical Necessity (* indicates required field)

The following does not suggest approved uses or indications.

Diagnosis:
- Chronic thromboembolic pulmonary hypertension
- Pulmonary arterial hypertension
- Other
- Inoperable
- After surgical treatment

Pulmonary hypertension status:
- Newly diagnosed
- Previously diagnosed

7 Written Permission to Share Information

I authorize my VA healthcare provider, and VA pharmacy to share my name, address, and phone number, along with my prescription and treatment information relating to my use or need for Adempas with Bayer and its agents and contractors (collectively “Bayer”) for purposes of actividades related to the quality, safety, or effectiveness of such FDA-regulated product and my potential pregnancy status at any given point. I understand that certain healthcare providers, such as my pharmacists, may receive payment from Bayer in connection with the disclosure of my information as I allow through this authorization.

I allow my information to be shared with Bayer so that it may: 1) communicate with me and my healthcare providers about my medical care, and 2) learn how well Adempas, the Adempas REMS, or Adempas Program is working.

This authorization expires at the end of my participation in the Adempas Program or 10 years after the date I sign it if earlier. I can cancel this authorization earlier by contacting my VA healthcare provider. The cancellation will not apply to information already released by my healthcare providers, pharmacies, and health plans and before they learn about my cancellation. Once my information is disclosed to Bayer it will no longer be protected by federal privacy laws and my information may be given out (re-disclosed) by Bayer. However, I understand that Bayer will make every effort to keep my information confidential and only use and share it for the purposes stated in this authorization. I may refuse to sign this form, and this refusal will not affect my treatment, payment for treatment, enrollment in a health plan, or eligibility for benefits. I understand I am entitled to receive a copy of this authorization once signed.

8 Please forward this completed document to the VA pharmacy for review. If appropriate, the VA pharmacy will relay to the Adempas Program at 1-855-662-5200

To report any adverse events, product technical complaints, medication errors or pregnancies associated with the use of Adempas, contact: Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.

Phone: 1-855-4ADEMPAS (1-855-423-3672) www.adempasREMS.com Fax: 1-855-662-5200

Reference ID: 3522688
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY R SOUTHWORTH
06/11/2014